Prostate-specific membrane antigen and uses thereof
US7399461B2 · kind B2 · utility
35Cited by
49References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 2, 2003 |
| Grant date | Jul 15, 2008 |
| Priority date | — |
| Expiry date | Aug 19, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/342
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method of administering methotrexate triglutamate (MTXglu3), an inhibitor of the neurocarboxypeptidase activity of prostate specific membrane antigen, to a subject so as to inhibit release of glutamate by N-acetylaspartylglutamic acid (NAAG) hydrolysis in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.